Oral contraceptive formulation and risk of breast cancer.

Authors

Polly A. Marchbanks, Centers for Disease Control, Atlanta, Georgia
Katheryn M. Curtis, Centers for Disease Control, Atlanta, Georgia
Michele G. Mandel, Centers for Disease Control, Atlanta, Georgia
Hoyt G. Wilson, Centers for Disease Control, Atlanta, Georgia
Gary Jeng, Centers for Disease Control, Atlanta, Georgia
Suzanne G. Folger, Centers for Disease Control, Atlanta, Georgia
Jill A. McDonald, Centers for Disease Control, Atlanta, Georgia
Janet R. Daling, Fred Hutchinson Cancer Research Center
Leslie J. Bernstein, Beckman Research Institute, City of Hope, Duarte, CA
Kathleen E. Malone, Fred Hutchinson Cancer Research Center
Phyllis A. Wingo, Centers for Disease Control, Atlanta, Georgia
Michael S. Simon, Wayne State UniversityFollow
Sandra A. Norman, University of Pennsylvania
Brian L. Strom, University of Pennsylvania
Giske A. Ursin, Cancer Registry of Norway, Oslo, Norway
Linda K. Weiss, National Institute of HealthFollow
Ronald T. Burkman, Tufts University School of Medicine
Robert Spirtas, George Washington University

Document Type

Journal Article

Publication Date

4-2012

Journal

Contraception

Volume

Volume 85, Issue 4

Inclusive Pages

342-350

Keywords

Breast Neoplasms--chemically induced; Contraceptives; Oral--adverse effects; Contraceptives; Oral; Hormonal--adverse effects

Comments

This is an open access PubMed Central article. Click on link for full-text access.

APA Citation

Marchbanks, P. A., Curtis, K. M., Mandel, M. G., Wilson, H. G., Jeng, G., Folger, S. G., . . . Spirtas, R. (2012). Oral contraceptive formulation and risk of breast cancer. Contraception, 85(4), 342-350.

Peer Reviewed

1

Open Access

1